The Safety and Efficacy of 12 Versus 24 Hours of Tirofiban Infusion in Patients Undergoing Primary Percutaneous Coronary Intervention

---

Topcu S., Karal H., Kaya A., Bakirci E. M., Tanboga I. H., Kurt M., ...Daha Fazla

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, cilt.21, sa.8, ss.783-789, 2015 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 21 Sayı: 8
• Basım Tarihi: 2015
• Doi Numarası: 10.1177/1076029614529841
• Dergi Adı: CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Sayfa Sayıları: ss.783-789
• Anahtar Kelimeler: tirofiban infusion, ST-segment elevation myocardial infarction, primary percutaneous, coronary intervention, IIB/IIIA RECEPTOR ANTAGONISTS, GLYCOPROTEIN IIB/IIIA, MYOCARDIAL-INFARCTION, DOUBLE-BLIND, METAANALYSIS, IMPLANTATION, EPTIFIBATIDE, INHIBITORS, ABCIXIMAB, PLACEBO
• Atatürk Üniversitesi Adresli: Evet

Özet

Aim: We aimed to investigate the 6-month efficacy and safety of postprocedural 12-hour tirofiban administration versus 24-hour tirofiban administration in patients with ST-segment elevated myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI).